Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wontran CR Tab is a fixed-dose combination of **tramadol hydrochloride**, a centrally acting opioid analgesic, and **acetaminophen** (paracetamol), a non-opioid analgesic and antipyretic. Developed by **Daewon Pharm**, it is formulated as a controlled-release tablet designed to provide sustained pain relief for moderate to severe acute and chronic pain. Tramadol exerts its effects as a mu-opioid receptor agonist and a weak inhibitor of norepinephrine and serotonin reuptake, while acetaminophen's mechanism primarily involves the inhibition of prostaglandin synthesis in the central nervous system. This combination leverages synergistic effects to improve analgesic efficacy while potentially reducing the required dose of the opioid component, thereby minimizing opioid-related side effects. The controlled-release formulation allows for less frequent dosing compared to immediate-release versions, improving patient compliance in chronic pain management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + acetaminophen.